FemPulse Corporation announced completion in the first quarter of 2018 of a private financing round, which will enable acceleration of the development of its novel and proprietary bioelectronic therapy for overactive bladder (OAB) in females. Proceeds will be used for technical and clinical evidence development in preparation for commercialization of the therapy in the US and EU.
